Why IMU is a multi multi bagger, page-22181

Continuing on from your initial points Choccy Teapot, I've done some very quick / elementary google searches on the other researchers named on the CF33 paper.

A.F. Shields - 17k citations, specialist areas seem to be lung, colorectal and small intestine cancers.

D. Li - pancreatic cancer?

H. Mamdani - Mamdani specializes in thoracic oncology, particularly lung cancer and mesothelioma (and breast cancer?)

A. Spira - advanced non-small cell lung cancer (NSCLC), pancreatic, or colorectal cancer

G. Daniels - UC San Diego - Dr. Daniels coordinates our clinical program in melanoma. His own research involves understanding the link between autoimmunity and tumor immunity in developing more effective and less toxic vaccines and immune stimulatory approaches for patients with melanoma.

J. Merchan - advanced pancreatic adenocarcinoma, involved in 2023 study titled "Targeting immunosuppressive adenosine to enhance vaccinia virus renal cancer oncolysis in vivo" which could be Cf33?

A. Kumar - Kumar's clinical expertise includes surgical treatment of: Ovarian/fallopian tube/peritoneal cancer; Endometrial/uterine cancer; Ovarian cysts and masses, I have clinical expertise in the diagnosis and treatment of both Hodgkin and non-Hodgkin lymphoma and my research focus is on mantle cell lymphoma.

E. Lim - St Vincent's Hospital - Associate Professor Elgene Lim is a medical oncologist and scientist with a focus on breast cancer research and treatment.

S. Hamilton - multiple results for this name so will omit from sharing.

S. Yavrom - lots came up related to IMU inclduing Cf33 as a monotherapy for gastrointestinal malignancies (Jan 2024), Hervaxx, Imprinter - seems Yavrom is well-involved with IMU research which makes sense.

S. Fein - breast and prostate cancer?

J. Byon - Immunotherapy for Non-small-cell Lung Cancer (2017), breast cancer research? IMU appointed Senior Vice President of Clinical Development (this name is new to me, only discovered through this google search)

P. Woodward - IMU's esteemed Chief Medical Officer

J. Leddon - again, involved heavily in IMU research. This popped up from 2022 - "The molecular and immune landscape of recurrent head and neck squamous cell carcinoma (HNSCC) in patients undergoing definitive therapy"

G. A. Wilkinson - member of the American Lung Association.

Please be mindful my google searches have been brief and rudimentary. It may well be a self-fulfilling exercise in google searching cancer researchers involved with Cf33 research studies to find that they are heavily involved in IMU product trials. For mine, it seems lung and breast cancer have popped up a number of times, as well as colorectal, gastrointestinal and melanoma. I'm just adding fuel to the speculation, I think it's difficult to draw conclusions from my elementary googling.

Regardless of the above speculation, I'm feeling excited to see what Imugene presents, only a week to wait!!

DYOR, mine has its limitations. GLTAH.